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a  b  s  t  r  a  c  t
Hepatitis  E virus  (HEV)  was discovered  in the  1980s  and  has  been  considered  as  being conﬁned  to devel-
oping  countries.  The  purpose  of  this  critical  review  was  to  determine  the  reported  HEV  seroprevalence
rates  in  Italy,  to identify  predisposing  factors  and  individuals  at risk and  to assess  possible  importation
of  HEV  by  immigrants.  A  critical  review  of 159  articles  published  in PubMed  from  1994  to  date  was
done.  Only  27 original  reports  of  50 or more  subjects,  written  in  the  English  or Italian  language,  were





being  reported  from  the central  region  of  Italy.  Risk  factors  included  ingestion  of raw  pork  or  potentially
contaminated  food.  The  seroprevalence  among  immigrants  ranged  from  15.3%  to  19.7%  in Apulia.  Italy  has
a population  of  60 656 000;  the total  number  of  individuals  surveyed  was  only  21.882  (0.036%).  A  national
epidemiological  survey  program  is  needed  to capture  more  comprehensive  seroprevalence  data.
©  2017  The  Authors.  Published  by Elsevier  Limited  on  behalf  of King  Saud  Bin Abdulaziz  University
for  Health  Sciences.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ontents
Introduction  . . . .  .  . .  .  . .  .  . . .  .  . . .  .  . . .  . . . . .  . . . . . .  .  . .  .  .  . .  .  .  . .  .  .  . . . . .  . .  . .  . . . .  .  . . . . . .  .  . .  . . . . .  .  . . . .  .  . .  . .  . .  . . . .  . . .  . . .  .  . . .  . . . .  .  . . .  . . . .  .  . . . . . . . . . .  . . .  .  .  .  .  . .  .  .  . . . .  . . . .  . .  1
Methods  . .  .  . . .  . .  . .  .  . . . .  .  . . . .  . . .  . . . .  .  . .  .  . . .  . . . . . .  .  .  . .  .  .  . . .  . . . . . . .  . . . . . . . .  . . . .  . .  . . . . . . .  .  . . . . . . .  .  .  . . .  .  .  . . . . . .  .  . . . . . . .  . . .  .  . . . . .  .  . .  . . .  .  . . . . . .  . . . . . .  .  .  .  .  . . .  . .  . . . . . 2
Results  . . .  .  . . .  . . . .  . . . .  .  . . .  . . . .  . . . . . . .  . . .  .  . . .  .  . . .  .  . . .  . . . .  . . .  .  . . . .  . . .  . . . . . . .  .  . . .  . . .  . . . .  . . .  . . . . . . .  . . . . . . . . . .  . . . . .  .  . .  . . . . . . .  . . . . .  .  . . .  .  .  .  . . .  .  . . . . . .  . . .  .  .  .  . .  .  .  . . .  . . 2
Discussion  . .  . . .  . .  .  . . . .  . . .  .  . . .  . . . .  . . .  .  . . .  . . . .  . . . .  . . .  . . . .  .  . . .  . . . .  . . .  . . . .  . . . .  . . . . . . . .  . .  . . .  .  . . . .  . . .  . . .  . . .  .  . . .  . . . . .  . . .  . . . . .  . .  . . . .  .  . . . .  .  .  . . .  .  . . . . . .  . . .  .  .  .  .  . . .  . .  .  . . 4
Conclusion  .  . . . .  . . .  . . .  . . . .  . . . .  .  . . .  . . .  .  . . .  .  . . .  . . .  . . . . .  . . . .  . . .  .  . . . . . .  .  . .  . . . .  .  . . . .  . . .  .  . . . . . .  . . . . . . .  . . .  . . . . . . .  . .  . . .  . .  .  . . . . .  . .  .  . . .  .  .  . . .  .  . . . . .  .  . . .  .  .  .  . . .  .  .  . .  . . . .  .  . . 6
Funding.  . .  . .  .  . . . .  .  . .  . . .  .  .  . . . . . .  . . . .  . . .  .  . . .  .  . . .  .  . .  . .  . .  .  .  .  . .  . . .  . . .  .  . . . .  .  .  .  . . .  .  . . .  . . . . .  . . .  . .  . . .  . . . . .  . . .  . . . . . .  .  .  . .  .  . .  . .  . . .  . . .  .  .  .  .  .  . . . .  .  . . . . .  . .  .  .  . .  . .  . .  .  . .  . . .  .  .6
Competing  interests  .  . . . . .  . . .  .  . . .  .  . . .  . . .  . . . .  . . .  .  . . . .  . . . .  . . .  . . . .  . . .  . . .  . . . .  .  . . . .  . .  .  . . . . . .  .  . . . . . .  .  . . . .  .  . . .  . . . .  . . .  . .  . . . . .  .  . . .  . . . .  .  . .  .  . . . . . . . . . .  .  .  . .  . .  . .  .  .  . . . . .  . . 6
Ethical  approval  .  .  .  . .  . .  .  . . .  .  . . .  .  . . .  . . .  .  . . . . . .  .  . . . .  . . . .  . . . .  . . . .  . . . . . .  .  .  . .  . . . . .  . . . . . .  .  .  . . . . . . .  . . . . .  .  . .  . . .  . . .  . . . .  .  . .  . . . . . . . . . . . .  . . . .  .  . .  . . .  .  . . . . . .  . . .  .  . .  .  .  .  .  . . . . 6
Acknowledgments  . .  . . . . . . . . . .  .  . . .  .  . . .  .  . . .  . . . .  .  . . .  . . .  .  . . .  .  . . . . . .  . . .  . . . .  .  . . . .  . . .  . . . . . . .  . . .  . . . . .  . . .  . . . . . .  .  .  . . .  . .  .  .  . . .  . .  .  .  . . .  .  . . . .  .  .  .  . . .  .  . . .  . . .  . . .  .  . .  . . . .  .  . .  6
References  . . .  . .  .  .  . .  . .  .  .  . . .  . . .  .  . . .  . . . . . . . . . . .  . . .  .  .  . .  .  .  . .  .  .  . . . . . . .  . . .  . . . . .  .  .  . .  . . . .  . .  . . . . . .  .  . . . . . .  .  . . . .  .  . .  . . . .  .  . . .  . . . . . . .  . . .  .  . . . . . . .  . . . . .  . .  .  .  .  .  . . . .  . . . . . . . . .  . 6Abbreviation: Assay-1, Dia.Pro; Assay-2, Abbott; Assay-3, Wantai; Assay-4,
daltis; HEV, Hepatitis E virus.
∗ Corresponding author at: Johns Hopkins University School of Medicine, Pedi-
tric Liver Center, CMSC 2-116, 600 North Wolfe St. Baltimore, Md. 21287, USA.
ax: +1 410 955 1464.
E-mail addresses: carlo.mauceri89@gmail.com (C. Mauceri),
gclemente@uniss.it (M. Grazia Clemente), paolo.castiglia@uniss.it (P. Castiglia),
antonucci@uniss.it (R. Antonucci), kschwarz@jhmi.edu (K.B. Schwarz).
ttps://doi.org/10.1016/j.jiph.2017.08.004
876-0341/© 2017 The Authors. Published by Elsevier Limited on behalf of King Saud Bi
C  BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatitis E virus (HEV) is the ubiquitous etiological agent of
enteric non-A viral hepatitis and it represents an ongoing inter-
nationally challenging issue for public health. Annually, HEV is
responsible for 3.3 million new symptomatic infections with fatal
outcomes in 56 600 individuals worldwide [1,2]. Three decades
after its discovery during an outbreak of unexplained hepatitis in
Afghanistan [3], not only is its origin unknown but the modes of
transmission remain far from being clearly understood in the indus-
trialized world. HEV is a small hepatotropic single-stranded RNA
virus, the sole member of the Hepeviridae family, belonging to the
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epevirus genus [4]. The genetic variability of HEV, its host range,
s well as its classiﬁcation, has been in constant evolution [5]. Pre-
ious genomic sequence analysis had revealed the existence of four
ell-deﬁned mammalian genotypes and at least 24 sub-genotypes,
ith a speciﬁc geographic distribution [6]. Indeed, the epidemi-
logy and pathogenicity of HEV observes a bimodal pattern that
iffers in emerging nations and occidental countries. Genotypes 1
nd 2 cause large outbreaks and epidemics mainly among young
dults in Africa, Central and Southern Asia, Central America and
he Middle East [7–12]. The infection is acquired predominately
hrough a fecal–oral route and it is associated with an unusually
igh mortality rate during pregnancy [13]. Poor sanitation and con-
aminated water sources are precipitating factors. An increasing
umber of sporadic and small locally acquired outbreaks have been
eported in Northern America, Australia, Europe, China and Japan
14–19]. Genotypes 3 and 4 are less virulent strains identiﬁed as the
ausative agents of subclinical and clinical infection in the elderly
opulation. HEV is mostly transmitted zoonotically with the inges-
ion of raw and undercooked food. To data, eight genotypes have
een detected and 4 of which are conﬁned to animal species: geno-
ype 5 and 6 in Japanese wild boar (Scrofa scrofa leucomystax) [20]
nd genotype 7 and 8 respectively in dromedary camels (Camelus
romedaries) and Bactrian camels (Camelus bactrianus)  [21].
In Europe, HEV seroprevalence estimates ranged in the gen-
ral population from 7.5% to 31.9% with the average rate being
9.16%; rates increase with age [22]. However, the real prevalence
ould be underestimated due to the difference in test sensitivity
nd the frequently asymptomatic course of the disease. Overall,
t is likely that current geopolitical instability and the consequent
assive immigration would lead towards the local introduction of
ew pathogenic variants and modify the known epidemiology in
estern countries.
ethods
The critical review is based on a literature search on PubMed,
sing the keywords “hepatitis E in Italy” and “hepatitis E seropreva-
ence in Italy”. Studies published from January 1994 and May  2017
ere included according to the following criteria: studies provided
lear information regarding the seroprevalence rate at the regional
r national level and included at least 50 samples in the cohort
Fig. 1). No age restriction was observed and all studies were writ-
en in the English or Italian language. The statistical analyses of the
eported regional seroprevalences have been done. We  used the
creening methods to adjust the prevalence value according to the
ensitivity and speciﬁcity of the assay. Only estimated seropreva-
ence rates with a lower positive value for C.I. at 95% have been
onsiderate statistically signiﬁcant.
According to the data available, we focused on fourteen study
ohorts: general population, blood donors, pregnant women,
he pediatric population, acute hepatitis patients, chronic liver
isease patients, hemodialysis patients, immigrants, prisoners,
ntravenous drug users, HIV co-infected individuals, HIV-exposed
nd/or infected individuals and workers with contact with poten-
ial zoonotic reservoirs (abattoir workers, laboratory workers
xposed to biological swine material, animal breeders, veterinari-
ns and farmers) and recipients of renal transplants. Studies that
id not meet the above-mentioned criteria, provided duplicate
ata, personal opinion or international reviews, were excluded
rom the critical review.esults
159 publications were identiﬁed by title and abstract through
 PubMed search and 27 articles were included in the ﬁnal datand Public Health 11 (2018) 1–8
analysis. Based on data published in these articles, we calculated
that a total of 21.882 individuals have been tested for anti-HEV IgG
and/or anti-HEV IgM, representing only 0,036% of the current Italian
population [23]. The seroprevalence rates ranged from 0,12% to 49%
among the study cohort [24,25]. The Abruzzi region was  found to be
a hyper-endemic region with a seroprevalence rate of 49% among
blood donors [25]. A seroprevalence study of 132 blood donor resi-
dents in Tuscany has reported rates of 9.1% [26], which is similar to
the 9% rate of the same cohort of individuals in the Latium region in
2009 (further data not shown). [25]. A seroprevalence of 9% was also
reported in the general population of Abbiategrasso, in Lombardy;
the highest assessed among the northern regions of Italy [27]. Con-
versely, the lowest seroprevalence of 1.3% and 2.7% was  reported
in Piedmont and Apulia among the open population, respectively
in the north and south of Italy [28,29]. The highest rate among the
southern regions was reported in Calabria (Casanova) with a sero-
prevalence of 17.8% [27]. Based on the data on age reported by 17
of the 27 studies, we calculated a mean age of 42.28 years for the
HEV positive subjects. Moreover, 59,26% were males, according to
the information provided by 21 studies. Overall, the seroprevalence
increased in association with age and no relevant variation related
to gender has emerged from any study. However, only one pediatric
study with a prevalence of 0.4% was found in Molise [30].
The study included: 10.527 individuals from the general pop-
ulation cohort, 2776 blood donors, 352 pregnant woman, 264
individuals at pediatric age, 2.609 patients affected by acute hepati-
tis, 800 individuals in hemodialysis, 118 renal transplant recipients,
430 chronic liver disease patients, 371 at zoonotic risk workers, 510
immigrants and 3.125 at high-risk individuals (100 HIV  infected
and 1116 with sexual or occupational exposure, 936 intravenous
drug users and 973 prisoners).
The selected articles were from 13 different regional areas:
Abruzzi (n = 1), Apulia (n = 2), Calabria (n = 2), Latium (n = 2), Lom-
bardy (n = 3), Marche (n = 1), Molise (n = 1), Molise (n = 1), Piedmont
(1), Sardinia (n = 1), Sicily (n = 3), Republic of San Marino (n = 1),
Tuscany (n = 1), and Veneto (n = 2) (Fig. 2).
The remaining 7 studies provided information at a national level
only. Over three decades, 169 cases of hepatitis E were linked to
travel in high endemic countries. Nearly 90% of them occurred
in travelers returning from Bangladesh, India and Pakistan. The
remaining cases were diagnosed in patients who traveled in Angola,
Somalia, Morocco and Green Cape. Secondary and intra-familiar
infection has been described by two  studies with a rate of 2.6%
and 4.5% respectively [31,32]. Generally, a higher probability to be
positive for anti-HEV antibodies has been associated with immi-
grants by the different studies focusing on socio-economic and
demographic variables (healthy population, prisoners and at-risk
categories). Genotype 1 (G1), subtype 1a and 1c, has been isolated
in all imported cases of HEV. Genotype 3 (G3), subtype 3e, 3f and 3 h,
has been associated with a local source of infection. No signiﬁcant
differences in the clinical course of the disease caused by the G1
and G3 subtypes have been observed in immunocompetent indi-
viduals. Potential risk factors for HEV transmission included poor
sanitation, person to person contact, family with more than 4 mem-
bers, parenteral blood contact, male to male contact, professional
long exposure with zoonotic reservoirs and raw and undercooked
pork meat and shellﬁsh.
In order to assess the seroprevalence of hepatitis E, differ-
ent enzyme immunoassays (EIA) have been used to detect class
G and M immunoglobulins against HEV. The commercially avail-
able assays were based on two methodologies: ELISA and Western
Blot. The majority of studies (22 over 27) used one or more Elisa
assays [25–28,30–47], while in 5 articles were used both serolog-
ical assay types [24,29,48–50]. HEV RNA was detected if samples
were positive for IgM and/or IgG in 12 of the selected studies
[25,28,29,32,36,37,39,42,44,46,47,50].
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Fig. 1. Protocol utilized to select articles for the review.
Table 1
Comparative sensitivity of each commercial assay by regions and study population.
Assay Regions Study population (N) Anti-HEV HEV-RNA (%)
IgG (%) IgM (%)
Assay-1 aCalabria GP (876) b17.8% – –
aLombardy GP (2.489) b9.0% –
Sardinia BD (402) 5.0% – –
Sicilia  GP (44) 4.7% – –
Apulia  GP (450) 2.7% 0.22% 0.22%
BD  (151) 1.3% – –
Assay-2 Veneto GP (1.889) 2.6%
Republic of S. Marino GP (2.233) 1.5% – –
Molise  Ped (264) 0.4% – –
Assay-3 Abruzzi BD (313) b49.0% 0.6% 0.6%
Piedmont GP (73) 1.3% – –
Assay-4 Tuscany BD (132) 9.1% – –
GP: general population; BD: blood donors; Ped: pediatric study.
a Data from the same study [27].
b Seroprevalence rate with lower positive value at C.I. 95%.























qFig. 2. Map  of Italy showing different HEV seroposi
Table 1 shows the reported anti-HEV IgG seroprevalence accord-
ng to the assay used in the Italian regions. Assay 1 (Dia.pro) was
sed in the majority of studies and the reported seroprevalence var-
ed from 17.8% in Calabria to 2.7% and 1.3% in Apulia, respectively
ound in general population and blood donors [27,29]. Assay-2
Abbott) was used in three regions to detect the anti-HEV IgG in
wo studies among the general population (seroprevalence rang-
ng from 2.6% and 1.5%) and in a pediatric study (seroprevalence
.4%) in three regions [35,48,30]. The highest and the lowest sero-
revalence in general population were both detected by assay-3
Wantai), respectively in Abruzzi (49%) and in Piedmont (1.3%)
25,28]. Both the Abruzzi and Apulia studies have provided data
n anti-HEV IgM and HEV RNA with an overall prevalence ranging
rom 0.6% to 0.22%, among blood donors and general population,
espectively. In the former study the genotype found was 3 while in
he latter study was 1 [25,29]. A recent study on Italian blood donors
as compared the diagnostic performances of assay-1 and assay-
, demonstrating an overall concordance of 96%. Even thought
ssay-3 detected a slightly lower positivity rate than assay-1, no
igniﬁcant difference in sensitivity was observed [47]. However,
ur Bayesian analysis of the reported seroprevalence rates, among
talian regions, has shown that the screening methodology was ade-
uate in term of speciﬁcity only in two studies. Thus, the estimatedrates among blood donors and general population. .
HEV prevalence in Abruzzi, Calabria and Lombardy reﬂects the real
spreading of infection [25,27].
Discussion
To the best of our knowledge, the current article represents the
ﬁrst critical review of HEV IgG seroprevalence in Italy. The sera
samples of 21.882 individuals were collected from 1978 to 2015
as reported in the 27 publications included in the ﬁnal analysis.
The seroprevalence ranged from 0.12% to 49% with the highest
rates being in the central region. However, a great geographical
variability was observed among the Italian regions with a average
prevalence of 10,25% among blood donors. These ﬁndings lay the
groundwork for the hypothesis that diverse predisposing factors
such as dietary habits, environmental characteristics, different dis-
tributions of zoonotic reservoirs, contaminated surface waters, the
socio-economic and hygienic level, would sustain the spreading of
HEV infection along the Italian regions interdependently.
The majority of autochthonous cases of HEV in Italy seem to be
due to the zoonotic transmission of the infection from domestic
and wild animals. To date, HEV infections have been demonstrated
in domestic pig, wild boars, rabbits, wild dears and goats in Italy
[51–55]. Not surprisingly, nearly half of the wild boars in the Latium
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Table  2
Laboratory diagnosis of HEV infection: Anti-HEV IgG Assays.
IgG assay Assay type Antigen for coating Strain Sensitivity Speciﬁcity
Abbott [91] – Recombinant ORF-2 and ORF-3 proteins Burmese 91% 96%
Adaltis (EIAgen) [92] Qualitative indirect Synthetic antigens from ORF-2 and ORF-3 – 80.% 62.9%
Dia.Pro [93] Qualitative indirect 4 synthetic peptides with conservative
epitopes of ORF-2 and ORF-3 Genotypes 1,
2, 3, and 4
Burmese and Mexican 98% 96%
DSI  [93] – Recombinant ORF-2 and ORF-3 peptides
Genotype 1,2 and 3
– 72% 99%
MP  Diagnostics [95] – 3 recombinant ORF-2 proteins and
33-amino acid sequence from ORF-3.
Genotype 2,3
– 98% 97%
Wantai [94] Qualitative indirect Recombinant ORF-2 protein (PE2)
Genotype 1
Chinese 99,80% 99.9%

















































CO2) from ORF-2 and O
egion and in Tuscany (central Apennines area), had serological
arkers of HEV infection [56,57]. A similar high seroprevalence was
emonstrated among swine in Southern (Calabria) and Northern
taly but was remarkably low Piedmont region [58–61]. More-
ver, in Northwestern Italy (Lombardy and Emilia Romagna), HEV
ontamination was demonstrated in the majority of slurry sam-
les from pig production facilities [62]. In addition, the majority of
ndigenous cases of acute HEV were clearly related to the ingestion
f raw or undercooked local pork meat [37]. HEV contamination
as been assessed in pork meat-derived products and in the Ital-
an production chain. Interestingly, a high nucleotide homology has
een proven in human, swine and contaminated food samples from
he same geographical regions and, as expected, intermixed swine
nd human genomic sequences were found [63–66]. In fact, the
nadequate cooking of commercially available pork products does
ot inactivate effectively HEV infectivity [67]. In order to prevent
ood-borne HEV infection, consuming these products cooked at a
emperature of 71 ◦C for a minimum of 20 min, has been exper-
mentally proven to be necessary [68]. Moreover, HEV has been
etected in bagged ready-to-eat (RTE) vegetables, posing a further
oncern regarding food safety and new potential consumers’ risks
69]. Genotype 3 appears to occur in the majority of the locally
cquired acute HEV cases, both in human and zoonotic reservoirs.
owever, genotype 4 has been recently reported as an emerging
ndigenous pathogen in Italy as well in France and Germany, and
t seems no longer conﬁned to Japan, China and Southeastern Asia
70,71]. In fact, a small outbreak was reported in the Latium region,
n 2011. The isolated strain differed genetically from the identiﬁed
uropean 4d and 4f strains and it resembled the subtype 4d strain
solated in China among the swine population [18]. Furthermore, a
enotype 4 strain, phylogenically related to the human strain iso-
ated during the outbreak in central Italy, was identiﬁed in swine
arms in Northern Italy and provided further evidence of a plausible
ross-species infection and introduction of a new HEV variant in a
ifferent geographic region [72].
Although the ingestion of shellﬁsh has been reported since 1980
s a risk factor in our cohort of patients with HEV, only lately has
ts role been assessed as an indicator of marine pollution [41]. The
ivalve molluscan shellﬁsh samples were analyzed in indepen-
ent studies in Italy, France, Spain and Denmark for their ability
o concentrate the viral particles ﬁltrated during the feeding pro-
ess [73–76]. However, all the aforementioned studies did not
upport the contamination of the marine environment. No posi-
ive samples collected in the potentially contaminated sites were
ound. This result could have been caused by either an undetectable
uantity of viral particles or a short-lived environmental persis-
ence of HEV. Nevertheless, a recent study in Shandong Province in
hina assessed the seroprevalence among 1028 seafood-processingenotype 1,3
workers of whom 22.20% were anti-HEV IgG antibody positive.
The increase in seroprevalence was  associated with working-time,
thus to a higher likelihood to being exposed to contaminated raw
seafood and semi-ﬁnished products [77]. Interestingly, time of
exposure was  the only independent variable linked with a higher
anti-HEV prevalence found in our cohort of workers at zoonotic risk
[28].
The waterborne route of infection has been largely recognized
globally. Still, its epidemiological impact in the industrialized coun-
tries is unknown. However, HEV particles have been traced in
the Latium region and in the Tiber River that runs from the cen-
tral Apennines region to the Tyrrhenian Sea, in Italy [78]. Overall,
these ﬁndings suggest that different factors could determine the
endemicity we observed in Italy and thus the need for further inves-
tigation.
A recent seroepidemiological study compared a group of res-
idents in two different regions: Lombardy (Abbiategrasso, Milan)
and Calabria (Cittanova); reporting a twofold increased HEV preva-
lence in in the southern region [27]. The authors have explained
the difference observed, as likely consequence of the lowest socio-
economic and hygienic/sanitary conditions in Calabria. Since only
the Dia.pro essay was  used to determine HEV IgG positive, the
result might to reﬂect the real spreading of HEV, with a north-to-
south gradient. According to this ﬁnding, the highest prevalence
observed among blood donors in Abruzzi region might be a conse-
quence of the inadequate sanitation and poor hygienic conditions
that followed the devastating earthquake that struck L’Aquila in
2009, causing over 80 000 evacuated from their homes, As mat-
ter of the fact, an increase of enteric transmitted diseases was
reported subsequently to the catastrophic environmental and geo-
logical changes [79]. Moreover, the high prevalence rate in the
Abruzzi region is likely due in part to the highly sensitive Wan-
tai assay used [80]. Both the reported IgM and RNA seroprevalence
among blood donors in Abruzzi region was  0.6% [25].
Furthermore, we  found a similar seroprevalence rate among vol-
unteer blood donors and the general population. This ﬁnding ought
to denote that this speciﬁc cohort could represent the prevalence
in the Italian population, in general [24,40]. Moreover, we observed
that in the majority of cases HEV infection was asymptomatic,
anicteric and self-limiting and a normal level of transaminases has
been also reported. On the other hand, this implies that the bio-
chemical and serological screening currently performed; in order
to select the healthy blood donors may  be unable to identity viremic
donors. Indeed, viremic blood donors with a normal ALT level have
been reported in Germany and Japan [81,82]. HEV RNA has been
detected in blood donations and cases of transfusion-transmitted
infection have been reported worldwide [83–87]. The contami-


















































[Fig. 3. Number of HEV studies in Italy over two and one-half decades.
ated blood could have an under-recognized role as a potential new
ource of infection and it requires further investigations in Italy.
We were unable to provide a clear understanding of the poten-
ial impact of the immigration phenomenon among the Italian
opulation since only two studies, in the same region, were
ncluded in the ﬁnal analysis [29,49]. However, according to a
ecent retrospective study on a small cohort of symptomatic
igrants, hepatitis E appeared to be the main cause of acute
iral hepatitis [88]. Nevertheless, 5% of 40 fecal samples, from
symptomatic immigrants were positive for HEV RNA supporting a
lausible role of immigrants as “ symptom-free HEV carriers” [89].
The current study suggests the existence of a great variability
n the seroprevalence of HEV in Italy. This result could be partially
xplained by the heterogeneity in the sensitivity and speciﬁcity of
he immunoassays used, by small number of studies included as
ell as the number of samples tested; and the narrow window of
ollecting samples period. All samples from the general population
nd the blood donors have been analyzed with four commercially
vailable ELISA test: Dia.pro, Abbott, Wantai, Adaltis. Performance
omparison among different assays was reported by a recent study,
hich showed a very good concordance between the Dia.pro and
antai assay [47].
The global burden of hepatitis E is still underestimated due to
he sub-optimal commercial assays available [90].
In fact, serological assays based on different genotypes, using
ecombinant proteins or synthetic peptides, vary greatly in term
f sensitivity and speciﬁcity (Table 2) [91–95]. Moreover, the assay
ensitivity is higher in symptomatic cases than in the asymptomatic
nes [91]. Nevertheless, the speciﬁcity of the screening methodol-
gy, to obtain valid value of HEV prevalence, differ according to
he infection endemicity. However, these limitations empathize
he necessity of a comparably standard seroprevalence study at
 national level, in order to estimate the real prevalence of Hep-
titis E and to create an interventional plan directed at a regional
evel. Clearly, different dietary habits can’t alone determine the
ariability observed in our studies.
onclusion
The World Health Organization deﬁnes as an emerging zoono-
is any disease that is “newly recognized or newly evolved, or has
hown an increase in incidence or expansion in geographical, host
r vector range” [96]. We  do not know whether HEV is truly an
merging infection or whether it is due to an increased awareness
nd understanding of HEV in the Western countries (Fig. 3).
Although a phylogenetic and evolutionary analysis has stated
hat HEV might have been present in the Italian territory since the
arly 90s, nowadays it remains a silent and understudied entity
66]. At the present, HEV is undoubtedly endemic in Italy. How-
ver, the lack of commercially approved diagnostic assays [95], the
[
[nd Public Health 11 (2018) 1–8
need for correct timing of the detection of HEV and the absence of
standard treatment have all made HEV one of the most unrecog-
nized infectious diseases. HEV should always be considered in the
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